Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 8/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9733253 | 0.78 | NPC1 (0.69) | NPC1RAB9AGRIN1GRIN2BKCNH2 | |
| SCHEMBL7245213 | 0.76 | NPC1 (0.42) | NPC1RAB9AGRIN1GRIN2BKCNH2 | |
| SCHEMBL9389817 | 0.74 | NPC1 (0.67) | ADRB1ADRB3ADRB2NPC1RAB9A | |
| SCHEMBL7245207 | 0.73 | NPC1 (0.48) | ADRB1ADRB3ADRB2NPC1RAB9A | |
| SCHEMBL7245209 | 0.72 | KCNH2 (0.51) | ADRB1ADRB3ADRB2NPC1RAB9A | |
| SCHEMBL7245211 | 0.70 | KDM4E (0.44) | ADRB1ADRB3ADRB2NPC1RAB9A | |
| SCHEMBL9387271 | 0.69 | NPC1 (0.68) | ADRB1ADRB3ADRB2NPC1RAB9A | |
| SCHEMBL8213400 | 0.69 | ADRB3 (0.67) | ADRB1ADRB3ADRB2LMNA | |
| SCHEMBL11696549 | 0.68 | ADRB3 (0.66) | ADRB1ADRB3ADRB2LMNA | |
| Hydrochloric Acid SCHEMBL11697572 | 0.68 | ADRB3 (0.66) | ADRB1ADRB3ADRB2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-03-06 | — | — | US | disclosed |
| WO-1999064045-A9 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE INC (US) | 2001-07-05 | — | — | WO | disclosed |
| EP-1089749-A1 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | Advanced Medicine, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1089749-A4 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE INC (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999064045-A1 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | SLC47A2, SLC8B1, SLC47A1 | ADRB1 1522/4885ADRB3 1428/4885ADRB2 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.